Welcome to our dedicated page for TRANSLATE BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TRANSLATE BIO stock.
Translate Bio (TBIO) delivers cutting-edge synthetic biology solutions through automated DNA/mRNA synthesis platforms. This news hub provides investors and researchers with essential updates on the company’s scientific milestones and strategic developments.
Access official press releases covering product innovations, financial results, and research partnerships. Our curated collection ensures you stay informed about Gibson SOLA platform advancements, BioXp system integrations, and key collaborations driving precision medicine breakthroughs.
Discover updates across critical categories including clinical trial progress, technology licensing agreements, and operational achievements. All content is sourced directly from verified corporate communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to Translate Bio’s latest developments in genetic synthesis technology. Regularly updated to serve as your primary resource for monitoring TBIO’s role in advancing high-throughput biomedical research.
Telesis Bio Inc. (NASDAQ: TBIO) announced the expansion of its BioXp® Select Kit product line with two new kits for DNA amplification and scale-up. These kits enable automated and on-demand synthesis of transfection-scale DNA from customers' own DNA fragments or plasmid DNA. This innovation is expected to significantly reduce the time and steps required for DNA cloning and scaling, enhancing research workflows. Telesis Bio plans to release additional BioXp® kits throughout 2023, which will further improve processes like NGS Library Preparation and CRISPR gRNA synthesis.
Telesis Bio Inc. (NASDAQ: TBIO) reported a record revenue of $9.5 million for 4QFY22, reflecting a remarkable 208% increase compared to 4QFY21. The company's BioXp revenue rose 158% to $3.4 million. Gross margin improved to 68%, up from 29% year-over-year, despite operating expenses increasing to $14.3 million. The net loss narrowed to $8.1 million from $12.5 million the previous year. For 2023, Telesis Bio expects total revenue exceeding $45 million and gross margin between 55% and 59%. The company is focused on strategic investments to drive long-term growth and profitability.
Telesis Bio Inc. (NASDAQ: TBIO) announced that Daniel Gibson, Ph.D., CTO and Co-founder, will present at the Festival of Biologics on March 21, 2023. His talk, titled “Building Biology Overnight”, will focus on overcoming synthesis bottlenecks using hands-free automated synthetic biology solutions, particularly the award-winning BioXp® platform. Dr. Gibson will showcase the new SOLA technology, enhancing DNA synthesis by efficiently assembling complex synthetic genes and mRNA templates through a pre-manufactured library of short DNA oligos. This innovation aims to expedite timelines for applications in vaccine and therapeutics development.
Telesis Bio Inc. (NASDAQ: TBIO) announced its participation at the RNA Leaders Europe Congress in Basel, Switzerland, on March 15, 2023, to showcase its benchtop automation solutions for mRNA synthesis. Presentations will include insights on optimizing CAR-T development workflows and addressing mRNA synthesis bottlenecks. The award-winning BioXp® system allows automated mRNA synthesis from sequence or plasmid DNA, enabling faster acquisition of mRNA in days instead of weeks. Dr. Todd R. Nelson, CEO, asserts that this technology is crucial for accelerating drug discovery, particularly in oncology and vaccine development.
FAQ
What is the current stock price of TRANSLATE BIO (TBIO)?
What is the market cap of TRANSLATE BIO (TBIO)?
